Latest Headlines
Age should not affect chemotherapy choice for stage IV lung cancer: guidelines
Early PET-CT predicts treatment response of head and neck cancer
Evidence scarce to support RF ablation of colorectal CA metastases in the liver
Casopitant helps curb chemotherapy emesis
Australian scientists plan to regrow breasts after cancer
NEWS PROVIDED BY 
VIEW ALL NEWSDiabetes impacts breast cancer chemotherapy outcomes
NEW YORK (Reuters Health) - Diabetes mellitus appears to have an adverse effect on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer, according to Houston-based researchers.
As Dr. Sharon H. Giordano told Reuters Health, "We found that diabetic patients with breast cancer have higher rates of chemotherapy-related toxicities. Clinicians must be aware that diabetic patients are more likely to experience toxicity and should monitor diabetic patients closely."
In a March 23rd online publication from the Journal of Clinical Oncology, Dr. Giordano of The University of Texas M. D. Anderson Cancer Center and colleagues report that they used a Medicare database to identify more than 71,000 patients aged 66 years or more with breast cancer stages I through III.
Almost 12,000 received chemotherapy and 21% of these patients were diabetic. Those with diabetes were less likely to receive anthracyclines or taxanes and were more likely to be hospitalized because of chemotherapy-related toxicity, infection, fever, neutropenia and anemia.
The diabetic patients were also more likely to be hospitalized for any cause (odds ratio, 1.32) and had higher all-cause mortality (hazard ratio, 1.35) than nondiabetic women.
In patients who did not receive chemotherapy, breast cancer-related mortality was similar in diabetics and nondiabetics. However, in the chemotherapy cohort, it was greater in diabetics (odds ratio, 1.20).
"Despite these findings," the researchers conclude, "patients with diabetes should continue to be offered standard chemotherapy regimens, because this study cannot definitely answer which chemotherapy offers the best risk-benefit ratio for patients with diabetes."
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
NEWS PROVIDED BY
TEXT SIZE 